Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo ® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

August 01, 2019 -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials